It’s thyroid cancer awareness month. Amanda M. Laird, MD, FACS, chief of endocrine surgery at Rutgers Cancer Institute of New Jersey and associate professor of surgery at Rutgers Robert Wood Johnson Medical School, shares five facts about thyroid cancer everyone should know.
Esteemed clinicians and researchers recognized for their contributions to American Thyroid Association, thyroid cancer and thyroid disease research.
Results from the multi-cohort Phase I/II ARROW clinical trial, conducted by The University of Texas MD Anderson Cancer Center researchers, showed that a once-daily dose of pralsetinib, a highly selective RET inhibitor, was safe and effective in treating patients with advanced RET fusion-positive non-small cell lung cancer (NSCLC) and RET-altered thyroid cancer.
The American Thyroid Association (ATA) celebrates the recipients of the Women Advancing Thyroid Research Award. This award recognizes and honors the work of young women that are leading outstanding thyroid research.
Cancer cases in adolescents and young adults have risen by 30% during the last four decades, with kidney cancer rising at the greatest rate, according to researchers at Penn State College of Medicine.
American Thyroid Association to host ATA Alliance for Thyroid Patient Education Health Forum on Saturday, November 14, 2020 from noon – 1:15pm EST. Clinicians, Patient Advocates, Patients, and Families invited to participate.
The thyroid is a key part of the endocrine system, a small gland at the base of your neck that produces a hormone that helps control your body’s metabolism. One of the most common and treatable cancers in the United States is thyroid cancer. Rutgers Cancer Institute expert discusses research and treatment for this disease.
For patients with non-small cell lung cancers marked by RET gene fusions, the targeted therapy selpercatinib was well tolerated and achieved durable objective responses, or tumor shrinkage, in the majority of patients in a Phase I/II trial.
Up to one-third of physicians reported sending patients for a thyroid ultrasound for reasons not supported by clinical care guidelines, a new study led by University of Michigan Rogel Cancer Center researchers finds. Routine use of ultrasounds to detect cancerous thyroid nodules have led to a significant increase in thyroid cancer cases in recent years, although many are low-risk and unlikely to cause serious harm.
The targeted therapy pralsetinib appears to have high response rates and durable activity in patients with a broad variety of tumors harboring RET gene fusions, according to results from the international Phase I/II ARROW trial, led by researchers at The University of Texas MD Anderson Cancer Center.
Despite excellent prognosis with most thyroid cancers, many newly diagnosed patients have cancer-related worry, and physicians vary in their responses to patients’ worry, according to new research accepted for presentation at ENDO 2020, the Endocrine Society’s annual meeting, and publication in a special supplemental section of the Journal of the Endocrine Society.
When the thyroid and parathyroid glands don’t work well, the entire body feels out of balance. To tackle thyroid and parathyroid diseases, Nathan Boyd, MD, recently launched the UNM Thyroid and Parathyroid Surgery Program, housed at the UNM Comprehensive Cancer Center, to offer state-of-the-art treatments for these diseases.
A study led by The University of Texas MD Anderson Cancer Center furthered understanding about mitochondria, the cell components known as the “powerhouse of the cell.” Knowing more about the genome is crucial given that mitochondria play important roles in tumorigenesis.
Responders who worked at the World Trade Center site after the attacks on September 11, 2001, have an increased overall cancer incidence compared to the general population, particularly in thyroid cancer, prostate cancer, and, for the first time ever reported, leukemia, according to a Mount Sinai study published in JNCI Cancer Spectrum in January.
Researchers from Penn State College of Medicine identified a new gene mutation that may cause a type of familial thyroid cancer.
The American Thyroid Association will hold its 89th Annual Meeting on October 30-November 3, 2019, at the Sheraton Grand Chicago in Chicago, Illinois. In addition to hearing major speeches and awards, attendees can view the following oral presentations on thyroid cancer.###The American Thyroid Association® (ATA) is dedicated to transforming thyroid care through clinical excellence, education, scientific discovery and advocacy in a collaborative community.